Cellares Unveils State-of-the-Art Smart Factory in New Jersey
Cellares has inaugurated a groundbreaking Smart Factory in Bridgewater, New Jersey, marking a significant advancement in the state’s biotech sector and promising new hope for patients requiring advanced cell therapies. Fabian Gerlinghaus, CEO and co-founder, articulated the company’s vision during the launch event attended by key local and state figures, emphasizing their commitment to accelerating the availability of critical cell therapies globally. Situated at a former Pfizer site, the 118,000-square-foot facility represents the first of its kind—a fully integrated development and manufacturing space dedicated to large-scale cell therapy production.
Innovations in Cell Therapy Production and Job Creation
The new facility introduces the Cell Shuttle system, a pioneering modular platform designed for high-capacity cell therapy production. Powered by sophisticated robotics and software, this system can potentially handle over 40,000 therapy batches annually, with ambitions to expand to 100,000. This innovation not only catapults Cellares to the forefront of cell therapy manufacturing but also forecasts the creation of 350 jobs, reinforcing New Jersey’s economic growth and technological prowess in the healthcare sector.
Strategic Impact and Collaborative Ventures in Cell Therapy
Cellares’ Bridgewater facility has already begun to make its mark, not only by enhancing local job prospects but also by setting new standards in efficient, automated biomanufacturing processes. The site is designed to accommodate 50 Cell Shuttles, each capable of processing multiple batches simultaneously, drastically reducing labor needs and facility size. Additionally, a strategic partnership with Bristol Myers Squibb exemplifies the facility’s role in advancing cell therapy technologies, providing swift, scalable solutions to meet urgent global demands in healthcare.